Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Depreciation & Amortization (CF) (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Depreciation & Amortization (CF) for 11 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 7.25% to $2.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.8 million through Dec 2025, down 4.73% year-over-year, with the annual reading at $9.8 million for FY2025, 5.04% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $2.4 million at Intellia Therapeutics, down from $2.4 million in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $2.6 million in Q2 2024, with the low at $1.6 million in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $2.2 million, with a median of $2.2 million recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) increased 22.6% in 2023, then dropped 7.69% in 2025.
  • Over 5 years, Depreciation & Amortization (CF) stood at $1.9 million in 2021, then rose by 7.52% to $2.0 million in 2022, then increased by 22.6% to $2.5 million in 2023, then grew by 3.05% to $2.6 million in 2024, then fell by 7.25% to $2.4 million in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $2.4 million, $2.4 million, and $2.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.